Merck will acquire Oncolmmune, which recently announced positive findings from a Phase 3 study of its candidate for the treatment of patients with severe and critical COVID-19.
Genentech’s Xofluza now is indicated to include post-exposure prevention of influenza for patients 12 years old and older after contact with a person with the flu.
Pfizer is alleging that Aurobindo and Dr. Reddy's were planning separately to come out with generic versions of
Ibrance before expiration of its patent.